Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase

03:21pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.
Alcon Inc. (ALC) CEO David Endicott on Q4 2021 Results - Earning Call Transcript

Alcon stock up 5% after hours following Q4 earnings beat (ALC)

09:56pm, Tuesday, 15'th Feb 2022 Seeking Alpha
Alcon stock is trading 5% higher in after-hours trading after the company reported Q4 2021 earnings that beat on both the bottom and top lines.
Alcon press release (ALC): Q4 Non-GAAP EPS of $0.56 beats by $0.06.Revenue of $2.13B (+10.4% Y/Y) beats by $30M.FY22 Guidace:Net sales of $8.7B-$8.9B.Core EPS of $2.35-$2.45.

Alcon Reports Fourth Quarter and Full Year 2021 Results

09:30pm, Tuesday, 15'th Feb 2022 Business Wire
GENEVA--(BUSINESS WIRE)--Alcon Reports Fourth Quarter and Full Year 2021 Results

Alcon Q4 2021 Earnings Preview

10:35pm, Monday, 14'th Feb 2022 Seeking Alpha
Alcon (NYSE:ALC) is scheduled to announce Q4 earnings results on Tuesday, Feb. 15, after market close.The consensus EPS estimate is $0.50 (+11.1% Y/Y)
BMEZ: Buy Low, Hold For The Distribution And Rebound

Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise

04:28pm, Wednesday, 19'th Jan 2022 Zacks Investment Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief

01:29pm, Friday, 14'th Jan 2022 Zacks Investment Research
Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.
Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.

Alcon launches Systane Complete eye drops in Europe

07:02pm, Wednesday, 12'th Jan 2022 Seeking Alpha
Alcon <> announced the European launch of its dry eye product, Systane Complete Preservative-Free Lubricant Eye Drops, in a multi-dose bottle
Alcon Inc. - Registered Shares (ALC) shares closed today at 0.8% below its 52 week high of $88.78, giving the company a market cap of $43B. The stock is currently up 33.7% year-to-date, up 32.5% over the past 12 months, and up 52.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.3%, and the S&P 500 rose 1.2%. Trading Activity Trading volume this week was 47.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE